Role of the hemopexin domain of matrix metalloproteinases in cell migration

Journal of Cellular Physiology

Volumn 217, Issue 3, 2008, Pages 643-651

  Dufour, Antoine ^a   Sampson, Nicole S ^a   Zucker, Stanley ^a,b   Cao, Jian ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; HEMOPEXIN; HEMOPEXIN INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 28; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; ENZYME INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME DEGRADATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL ADHESION; CELL MOTION; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; METABOLISM; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME INHIBITORS; ENZYME PRECURSORS; HEMOPEXIN; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION;

EID: 54049107708     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21535     Document Type: Article

References (45)

1. Abecassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. 2003. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 291:363-376.
2. Albrect-Buehler G. 1997. The phagokinetic tracks of 3T3 cells. Cell 11:395-404.
3. Allan JA, Docherty AJP, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G. 1995. Binding of gelatinases A and B to type-1 collagen and other matrix components. Biochem J 309:299-306.
4. Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI. 2002. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 277:16022-16027.
5. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
6. Bjorklund M, Koivunen E. 2005. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755:37-69.
7. Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grotzinger J, Roeb E. 2007. MMP-9-hemopexin domain harpens adhesion and migration of colorectal cancer cells. Int J Onc 30:985-992.
8. Cao J, Rehemtulla A, Bahou WF, Zucker S. 1996. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 271:30174-30180.
9. Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zuckers S. 1998. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem 273:34745-34752.
10. Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C. 2005. Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 280:10974-10980.
11. Cha H, Kopetzki E, Huber R, Lanzendorfer M, Brandstetter H. 2002. Structural basis of adaptive molecular recognition by MMP-9. J Mol Biol 320:1065-1079.
12. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. 1990. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265:5267-5272.
13. Chitaley K, Wingard C, Webb R, Branam H, Stopper V, Lewis R, Mills T. 2001. Antagonism of Rho-kinase stimulate rat penile erection via a nitric oxide-independent pathway. Nat Med 7:119-122.
14. Di Girolamo N, Indoh I, Jackson N, Wakefield D, McNeil HP, Yan W, Geczy C, Arm JP, Tedla N. 2006. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: Role in cell migration. J Immun 177:2638-2650.
15. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689.
16. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
17. Goldberg G, Strongin A, Collier IE, Genrich T, Marmer B. 1992. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267:4583-4591.
18. Gross J, Lapiere C. 1962. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc Natl Acad Sci USA 48:1014-1022.
19. Hu Y, Ivashkiv L. 2006. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-α dendritic cells. J Immunol 176:6022-6033.
20. Hu J, Van den Steen P, Sang Q-X, Opdenakker G. 2007. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480-498.
21. Iyer S, Visse R, Nagase H, Acharya KR. 2006. Crystal structure of an active form of human MMP-1. J Mol Biol 362:78-88.
22. Jozic D, Bourenkov G, Lim N, Visse R, Nagase H, Bode W, Maskos K. 2005. X-ray structure of human proMMP-1. J Biol Chem 280:9578-9585.
23. Knight C, Willenbrock F, Murphy G. 1992. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 296:263-266.
24. Lee PPH, Hwang JJ, Murphy G, Ip MM. 2000. Functional significance of MMP-9 in tumour necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 141:3764-3773.
25. Lee M, Fridman R, Mobahery S. 2004. Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33:401-409.
26. Massova I, Kotra L, Fridman R, Mobashery S. 1998. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB journal 12:1075-1095.
27. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C. 2004. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J 23:3758-3768.
28. Nagase H, Woessner JF. 1999. Matrix metalloproteinases. J Biol Chem 274:21491-21494.
29. Nagase H, Visse R, Murphy G. 2006. Structure and function ofmatrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573.
30. Olson M, Bernardo M, Pietila M, Gervasi D, Toth M, Kotra L, Massova I, Mobashery S, Fridman R. 2000. Characterization of the monomeric and dimeric forms of latent and active Matrix Metalloproteinase-9. J Biol Chem 275:2661-2668.
31. Opdenakker G, Van Damme J. 2002. Chemokines and proteinases in autoimmune diseases and cancer. Verh K Acad Geneeskd Belg 64:105-136.
32. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French D, Quigley J. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076.
33. Ridley A, Schwartz M, Burridge K, Firtel R, Ginsberg M, Borisy G, Parsons J, Horwitz AR. 2003. Cell migration: Integrating signals from front to back. Science 302:1704-1709.
34. Rosenblum G, Van den Steen P, Cohen S, Grossmann G, Frenkel J, Sertchook R, Slack N, Strange R, Opdenakker G, Sagi I. 2007. Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 15:1227-1236.
35. Sanceau J, Truchet S, Bauvois B. 2003. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 278:36537-36546.
36. Schulz R. 2007. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approches. Annu Rev Pharmacol Toxicol 47:211-242.
37. Steffensen B, Wallon UM, Overall CM. 1995. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 270:11555-11566.
38. Sternlicht M, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
39. Tian Y, Chen Y, Chang C, Hung C, Wu M, Phillips A, Yang C. 2007. Epidermal growth factor and transforming growth factor-beta1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp Cell Res 313:2367-2377.
40. Van den Steen P, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, Moestrup S, Fry S, Royle L, Wormald M, Wallis R, Rudd P, Dwek R, Opdenakker G. 2006. The hemopexin and O-glycosylated domains tune gelatinase/MMP-9 bioavailibility via inhibition and binding to cargo receptors. J Biol Chem 281:18626-18637.
41. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5141-5148.
42. Zucker S, Lysik R, Zarrabi M, Moll U. 1993. Mr 92,000 Type IV collagenase is increased in plasma of atients with colon cancer and breast cancer. Cancer Res 53:140-146.
43. Zucker S, Conner C, DiMassimo BI, Ende H, Drews M, Seiki M, Bahou WF. 1995. Thrombin induces the activation of progelatinase A in vascular endothelial cells. J Biol Chem 270:23730-23738.
44. Zucker S, Hymowitz M, Conner C, Zarrabi H, Hurewitz A, Matrisian L, Boyd D, Nicolson G, Montana S. 1999. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: Clinical and experimental applications. Ann NY Acad Sci 878:212-227.
45. Zucker S, Cao J, Chen WT. 2000. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-6650.